This blog is written by our clinicians and aims to keep patients informed with up to date information on medical conditions.
Addenbrooke’s Hospital in Cambridge, UK, is currently conducting a clinical trial for a new device called CUE1 that has the potential to improve the treatment of Parkinson’s disease. The device is a wearable device that uses artificial intelligence (AI) to monitor a patient’s movements and provide personalized feedback to help manage their symptoms.
Parkinson’s disease is a progressive neurodegenerative disorder that affects millions of people worldwide. It is characterized by a loss of motor control, tremors, and stiffness. While there is no cure for Parkinson’s disease, there are several treatment options available, including medication and deep brain stimulation (DBS) surgery.
The CUE1 device is designed to complement existing treatments for Parkinson’s disease by providing personalized feedback to patients. The device is worn on the sternum of the chest and uses sensors to collect data on a patient’s movements throughout the day. The data is then analysed using AI algorithms to provide real-time feedback on a patient’s symptoms, including tremors, dyskinesia, and gait abnormalities. It then delivers vibration and pulses intended to improve motor skills and alleviate the stiffness.
The clinical trial at Addenbrooke’s Hospital will involve up to 10 patients with Parkinson’s disease who will use the CUE1 device for a period of six months. The primary outcome of the trial is to evaluate the safety and tolerability of the device. Secondary outcomes include improvements in motor symptoms, quality of life, and medication adherence.
The CUE1 device has the potential to be a valuable tool in the management of Parkinson’s disease. The personalized feedback provided by the device could help patients to better manage their symptoms and improve their overall quality of life. The device could also help to reduce the burden on healthcare systems by reducing the need for in-person visits and hospitalizations.
The clinical trial at Addenbrooke’s Hospital is an important step in evaluating the safety and effectiveness of the CUE1 device. If the trial is successful, the device could become a new treatment option for patients with Parkinson’s disease. The results of the trial are expected to be published in the coming years, and it will be interesting to see how the CUE1 device compares to traditional treatments such as medication and DBS surgery.
In conclusion, the CUE1 device is an innovative new device that has the potential to improve the management of Parkinson’s disease. The clinical trial at Addenbrooke’s Hospital is an important step in evaluating the safety and effectiveness of the device, and the results of the trial could have significant implications for the future of Parkinson’s disease treatment.
Written by Barbora Okasova – Physician Associate Trainee
References: Parkinson’s disease device trial at Addenbrooke’s Hospital – BBC News
What is the CUE1? | A Non-Invasive, Wearable Device for Parkinson’s (charconeurotech.com)
British hospital becomes first in the world to trial wearable tech for Parkinson’s patients | Evening Standard